LE 300
| Code | Size | Price |
|---|
| TAR-T22921-10mg | 10mg | £678.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
LE 300 represents a structurally novel type of antagonists acting preferentially at the dopamine D(1)/D(5)receptors and the serotonin 5-HT(2A)receptor.
CAS:
274694-98-3
Formula:
C20H22N2
Molecular Weight:
290.41
Pathway:
Neuroscience; GPCR/G Protein
Purity:
0.98
SMILES:
CN1CCc2c(Cc3ccccc3CC1)[nH]c1ccccc21
Target:
Dopamine Receptor; 5-HT Receptor
References
1. Rostom SA. Novel fused pyrrole heterocyclic ring systems as structure analogs of LE 300: Synthesis and pharmacological evaluation as serotonin 5-HT(2A), dopamine and histamine H(1) receptor ligands. Arch Pharm (Weinheim). 2010 Feb;343(2):73-80.
2. Kassack MU, et al. Pharmacological characterization of the benz[d]indolo[2,3-g]azecine LE300, a novel type of a nanomolar dopamine receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol. 2002 Dec;366(6):543-50.
3. Hefnawy M, et al. Spectrofluorimetric determination of dopamine receptor antagonist LE 300 in mice plasma. Luminescence. 2016 Feb;31(1):63-6.